Patents by Inventor Edward B. Reilly

Edward B. Reilly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20180125999
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: November 9, 2017
    Publication date: May 10, 2018
    Inventors: EDWARD B. REILLY, ANDREW C. PHILLIPS, LORENZO BENATUIL, FRITZ G. BUCHANAN, JONATHAN A. MEULBROEK, CHUNG-MING HSIEH, JENNIFER PEREZ
  • ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20170348429
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: May 17, 2017
    Publication date: December 7, 2017
    Inventors: EDWARD B. REILLY, LOUIE NAUMOVSKI, CHRISTIAN B. ALLAN, JIEYI WANG, MARK G. ANDERSON, DANIEL E. AFAR
  • Anti-EGFR antibodies and antibody drug conjugates
    Patent number: 9827330
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: November 28, 2017
    Assignee: Abbvie Inc.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • Prolactin receptor binding proteins and uses thereof
    Patent number: 9725515
    Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: August 8, 2017
    Assignee: AbbVie Inc.
    Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20170072065
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 16, 2017
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Fritz G. Buchanan, Jonathan A. Meulbroek, Chung-Ming Hsieh, Jennifer Perez
  • PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF
    Publication number: 20170022281
    Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
    Type: Application
    Filed: June 7, 2016
    Publication date: January 26, 2017
    Applicant: AbbVie Inc.
    Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. Digiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
  • Anti-EGFR antibodies and antibody drug conjugates
    Patent number: 9493568
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: November 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20160319026
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 5, 2016
    Publication date: November 3, 2016
    Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-Lappe, Jijie Gu
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20150337042
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 20, 2015
    Publication date: November 26, 2015
    Applicant: ABBVIE INC.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Fritz G. Buchanan, Jonathan A. Meulbroek, Chung-Ming Hsieh, Jennifer Perez
  • Dual variable domain immunoglobulins and uses thereof
    Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20150104452
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: June 10, 2014
    Publication date: April 16, 2015
    Inventors: Tariq Ghayur, Edward B. Reilly, Andrew Phillips, Randy L. Bell, Yingchun Li, Hua Ying, Susan E. Morgan-Lappe, Gillian A. Kingsbury, Jieyi Wang, Suzanne M. Norvell, Junjian Liu
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20150017168
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 15, 2015
    Applicant: ABBVIE INC.
    Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-Lappe
  • PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF
    Publication number: 20140227294
    Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
    Type: Application
    Filed: December 23, 2013
    Publication date: August 14, 2014
    Applicant: ABBVIE INC.
    Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. DiGiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110313230
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 22, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Stephen Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110293511
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 1, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan, Stephen Stockert
  • Dual Variable Domain Immunnoglobulins and Uses Thereof
    Publication number: 20110263827
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 30, 2010
    Publication date: October 27, 2011
    Applicant: Abbott Laboratories
    Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-lappe
  • BASIGIN BINDING PROTEINS
    Publication number: 20110223176
    Abstract: Isolated binding proteins, e.g., antibodies, which bind to Basigin (BSG), e.g., human BSG2, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: March 8, 2011
    Publication date: September 15, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Eve H. Barlow, Chung-Ming Hsieh, Denise D. Karaoglu Hanzatian, Gillian Ann Kingsbury, Susan E. Morgan-Lappe, Edward B. Reilly, Fritz G. Buchanan, Yingchun Li
  • Dual Variable Domain Immunoglobulins and Uses Thereof
    Publication number: 20100260668
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: October 23, 2009
    Publication date: October 14, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Tariq Ghayur, Susan E. Morgan-lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying, Zhihong Liu
  • Dual Variable Domain Immumoglobulins and Uses Thereof
    Publication number: 20100076178
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 28, 2009
    Publication date: March 25, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • ERYTHROPOIETIN RECEPTOR BINDING ANTIBODIES
    Publication number: 20090252746
    Abstract: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.
    Type: Application
    Filed: May 14, 2008
    Publication date: October 8, 2009
    Applicant: Abbott Laboratories
    Inventors: Peter J. DeVries, David H. Ostrow, Edward B. Reilly, Larry L. Green, James Wieler